Positive News Reported Regarding COVID-19 Vaccination Candidate

The New England Journal of Medicine (NEJM) published on September 2, 2020, additional details on the previously announced phase 1 study results, in which the coronavirus vaccine candidate NVX‑CoV2373 demonstrated a 'reassuring safety and reactogenicity profile and induced robust antibody responses numerically superior to that seen in human convalescent sera.'

The NEJM review concluded saying 'At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant-induced CD4+ T-cell responses that were biased toward a Th1 phenotype.' The NEJM authors did not report industry conflicts of interest.

Gregory M. Glenn, M.D., President of Research and Development at Novavax, said in a press statement, “Based on the positive Phase 1 results, we have begun multiple Phase 2 clinical trials."